Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNFX granules for common cold (heat type)
CTR20210793Phase 3Completed
- Sponsor
- Xinjiang Uygur Autonomous Region Institute of Drug Research
- Start
- Apr 2021
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in nasopharyngitis comparing BNFX granules with Placebo (BNFX granules simulant) (2 arms). Primary endpoint: Rate of complete symptom disappearance after 3 days of treatment. Started Apr 2021; status: completed.
02
Drugs
binafuxi
03
Conditions
nasopharyngitis
Beyond the preview
Go deeper on CTR20210793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210793.